Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Background. Several studies have reported that statins have anti-inflammatory effects. Nevertheless, results of clinical trials concerning the effect of statins on the levels of C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) have been inconsistent. Therefore, we performed a systematic review and meta-analysis of randomized clinical trials (RCTs) evaluating the effect of statins on CRP and hs-CRP levels in patients with cardiovascular diseases (CVDs). Methods. Literature search of the major databases was performed to find eligible RCTs assessing the effect of statins on serum levels of CRP and hs-CRP from the inception until the last week of April 2021. The effect sizes were determined for weighted mean difference (WMD) and 95% confidence intervals (CI). Results. 26 studies were identified (3010 patients and 2968 controls) for hs-CRP and 20 studies (3026 patients and 2968 controls) for CRP. Statins reduced the serum levels of hs-CRP ( WMD = − 0.97 mg / L ; 95% CI: -1.26 to -0.68 mg/L; P < 0.001 ) and CRP ( WMD = − 3.05 mg / L ; 95% CI: -4.86 to -1.25 mg/L; P < 0.001 ) in patients with CVDs. Statins decreased the serum levels of hs-CRP in patients receiving both high-intensity and moderate/low-intensity treatments with these drugs. In addition, the duration of treatment longer than 10 weeks decreased hs-CRP levels. Only high-intensity statin treatment could marginally decrease serum levels of CRP in CVDs patients. Conclusions. This meta-analysis showed the efficacy of statins to reduce the concentrations of CRP and hs-CRP in patients with different types of CVDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This has been confirmed in a recent meta-analysis that showed statins reduce hsCRP levels in patients with CV disease [6].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“to account for the effect of statins, which are known to reduce hsCRP levels [5, 6], a sensitivity analysis was conducted for the effect of treatment (semaglutide or comparators) on ratios to baseline by statin use (yes/no) at baseline.”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Accordingly, heterogeneity was considered significant if I2 was >50% and Cochrane’s Q was P < 0:10, while I2 < 50% and Cochrane’s Q (P > 0:10) did not prove a heterogeneity [41, 42].”
BackgroundQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Accordingly, heterogeneity was considered significant if I2 was >50% and Cochrane’s Q was P < 0:10, while I2 < 50% and Cochrane’s Q (P > 0:10) did not prove a heterogeneity [41, 42].”
BackgroundAtherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Jadad tool was used for evaluating the quality of RCTs by assessing the randomization, blinding, and dropouts (withdrawals) [40].”
MethodOperating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cited by
C-reactive protein: a target for therapy to reduce inflammation
Rizo-Téllez, S. A., Sekheri, M., & Filep, J. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237729 · Cited by 182
Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review
Banait, T., Wanjari, A., Danade, V., Banait, S., & Jain, J. (2022) · Cureus · doi:10.7759/cureus.30225 · Cited by 176
The interplay of factors in metabolic syndrome: understanding its roots and complexity
Islam, M. S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01019-y · Cited by 169
Surma, S., Sahebkar, A., & Banach, M. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106596 · Cited by 112
Self-citationMosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“Finally, to account for the effect of statins, which are known to reduce hsCRP levels [5, 6], a sensitivity analysis was conducted for the effect of treatment (semaglutide or comparators) on ratios to baseline by statin use (yes/no) at baseline.”
BackgroundResultCooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 83
“…macrophages and vascular smooth muscle cells, is a marker of systemic in fl ammation associated with formation and rupture of atherosclerotic plaques, promotion of occlusive thrombi, damage of vascular endothelial integrity, activation of the renin-angiotensin system and vascular remodeling 33 .”
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Zivkovic, S., Maric, G., Cvetinovic, N., Lepojevic-Stefanovic, D., & Bozic Cvijan, B. (2023) · Nutrients · doi:10.3390/nu15061517 · Cited by 71
“So far, statins exhibited anti-inflammatory effects and benefits in diseases related to inflammation: atherosclerosis [28], chronic heart failure [29], sepsis [30], COVID-19 [31], diabetic nephropathy [32], gastric cancer [33,34], Alzheimer’s diseases [35], bone disorders [36], and autoimmune diseases [37].”
BackgroundXie, S., Galimberti, F., Olmastroni, E., Lüscher, T. F., Carugo, S., Catapano, A. L., Casula, M., META-LIPID Group, Catapano, A. L., Casula, M., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae034 · Cited by 74
“24 on more than 40 studies, statins reduced the serum levels of CRP [ − 0.97 mg/L (95% CI − 1.26 to − 0.68)] in patients with CVD.”
BackgroundInfluentialKhan, S., Huda, B., Bhurka, F., Patnaik, R., & Banerjee, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178429 · Cited by 64
Cicero, A. F. G., Fogacci, F., Stoian, A. P., & Toth, P. P. (2023) · Nutrients · doi:10.3390/nu15102288 · Cited by 61
“Statins have been shown to reduce levels of the inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) [68], and this is also true of RYR, with reductions in hs-CRP versus placebo observed in subjects with mild hypercholesterolemia (−23.”
BackgroundSabeel, S., Motaung, B., Nguyen, K. A., Ozturk, M., Mukasa, S. L., Wolmarans, K. H., Blom, D. J., Sliwa, K. S., Nepolo, E., Günther, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323749 · Cited by 48
“It’s noteworthy that CRP, a non-specific marker of inflammation, is associated with CVD pathogenesis [46].”
Ding, Z., Wei, Y., Peng, J., Wang, S., Chen, G., & Sun, J. (2023) · Biomedicines · doi:10.3390/biomedicines11102711 · Cited by 46
“Statins reduce the production of IL-6 and reduce the number of LDL particles, thereby reducing the production of inflammatory mediators produced by CRP [131].”
BackgroundLong-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 38
“%) in hs-CRP levels compared with the placebo, irrespective of the type of drug, dosing frequency, changes in LDL-C levels, or cumulative dosage [42, 43].”
BackgroundGao, J., Lü, J., Sha, W., Xu, B., Zhang, C., Wang, H., Xia, J., Zhang, H., Tang, W., & Lei, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1015398 · Cited by 34
Regulatory impact of statins on macrophage polarization: mechanistic and therapeutic implications
Sadeghi, M., Khayati, S., Dehnavi, S., Almahmeed, W. A., Sukhorukovi, V. N., & Sahebkar, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae024 · Cited by 33
Self-citationRegulatory effects of statins on Akt signaling for prevention of cancers
Hosseini, F. S., Ahmadi, A., Kesharwani, P., Hosseini, H., & Sahebkar, A. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111213 · Cited by 30
Self-citationStroes, E. S. G., Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Laufs, U., Mancini, G. B. J., Ray, K. K., Sasiela, W. J., Zhang, Y., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.020 · Cited by 29
Kounatidis, D. C., Tentolouris, N., Vallianou, N. G., Mourouzis, I. S., Karampela, Ι., Stratigou, T., Rebelos, E., Kouveletsou, M., Stamatopoulos, V., Tsaroucha, E., et al. (2024) · Metabolites · doi:10.3390/metabo14070388 · Cited by 26
“This analysis found that treatment durations exceeding 10 weeks led to decreased hs-CRP levels, although only high-intensity statin regimens marginally reduced CRP serum concentrations in individuals with CVD [38].”
BackgroundNutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation
Surma, S., Sahebkar, A., & Banach, M. (2023) · Nutrients · doi:10.3390/nu15112629 · Cited by 24
Self-citationWang, L., Yang, L., Liu, H., Pu, J., Li, Y. W., Tang, L., Chen, Q., Pu, F., & Bai, D. (2023) · Brain Sciences · doi:10.3390/brainsci13071082 · Cited by 23
“It can be measured using a more sensitive method called high-sensitivity C-reactive protein (Hs-CRP), which can detect lower levels of CRP [8].”
MethodZhang, J., Wang, X., Tian, W., Wang, T., Jia, J., Lai, R., Wang, T., Zhang, Z., Song, L., Ju, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936817 · Cited by 21
Yi, M., Wu, L., & Ke, X. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9080247 · Cited by 18
“Another meta-analysis evaluating statin reduction in hs-CRP further suggested that statin therapy can reduce inflammation, reduce hs-CRP levels, and, ultimately, improve prognosis [35].”
BackgroundGholamalizadeh, H., Ensan, B., Sukhorukov, V. N., & Sahebkar, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgad112 · Cited by 19
Self-citationStatins and thyroid eye disease (TED): a systematic review
Malboosbaf, R., Maghsoomi, Z., Emami, Z., Khamseh, M. E., & Azizi, F. (2024) · Endocrine · doi:10.1007/s12020-023-03680-5 · Cited by 17
“So, statins may have in fl ammatory marker-lowering effects [36, 37].”
Xu, X., Liu, J., Sun, Y., Sun, P., & Yu, X. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335916 · Cited by 15
Lipid-lowering drugs and cancer: an updated perspective
Alizadehasl, A., Alavi, M. S., Boudagh, S., Alavi, M. S., Mohebi, S., Aliabadi, L., Akbarian, M., Ahmadi, P., Mannarino, M. R., & Sahebkar, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00553-6 · Cited by 15
Self-citationShahbaz, S. K., Koushki, K., Hedayati, S. K., McCloskey, A. P., Kesharwani, P., Naderi, Y., & Sahebkar, A. (2024) · Medicinal Research Reviews · doi:10.1002/med.22064 · Cited by 15
Self-citationCardiovascular disease in people living with HIV: Risk assessment and management
Ghandakly, E., Moudgil, R., & Holman, K. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24055 · Cited by 15
“18 In a primary analytic cohort of the FOURIER study (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk), Bohula et al 19 explored whether the association of infl ammation and risk of cardiovascular events persisted even at very low levels of LDL-C.”
Kamrani, F., Rezaee, A. M., Bigdeloo, L., Mojdehi, A. N., Darroudi, S., Talebkhah, M. H., Hadian, F., Hajian, A., Alizadeh, R., Alimi, H., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02627-1 · Cited by 15
“Therefore, statin treatment may lower hs-CRP levels, reduce inflammation, and lower the risk of CVD [30]. hs-CRP has commonly been used as a risk assessment tool for CVD and has been helpful for years for screening and primary prevention [31, 32].”
Arabi, S. M., Chambari, M., Malekahmadi, M., Bahrami, L. S., Hadi, V., Rizzo, M., & Sahebkar, A. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-01053-4 · Cited by 15
“A recent meta-analysis of RCTs has shown that statin therapy can reduce serum levels of CRP and hs-CRP by around 3 and 1 mg/l, respectively (Kandelouei et al. 2022), which can be regarded as clinically relevant.”
BackgroundInfluentialSelf-citationStatins, Allies against Antibiotic Resistance?
Abavisani, M., Hoseinzadeh, M., Khayami, R., Kodori, M., Soleimanpour, S., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230829141301 · Cited by 14
Self-citationStatin administration improves vascular function in heart failure with preserved ejection fraction
Iacovelli, J. J., Alpenglow, J. K., Ratchford, S. M., Craig, J. C., Simmons, J. M., Zhao, J., Reese, V. R., Bunsawat, K., Ma, C. L., Ryan, J. J., et al. (2024) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00775.2023 · Cited by 14
Xu, C., Mutwalli, H., Haslam, R., Keeler, J. L., Treasure, J. L., & Himmerich, H. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.039 · Cited by 14
Valibeygi, A., Fardaei, M., & Niknejad, S. (2025) · BMJ Neurology Open · doi:10.1136/bmjno-2024-000718 · Cited by 14
“…the systemic inflammation of the survivors may be diminished over time by devising secondary preventive measures, such as taking statins, as solid evidence supports this claim for CRP and hsCRP. 23 24 The significant association between SIRI and stroke history, however, should not be overlooked.”
Lundetræ, R. S., Lehmann, S., Saxvig, I. W., Saeed, S., Gíslason, Þ., & Bjorvatn, B. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.106529 · Cited by 14
Molaie, M., Lotfi, R., Moghadam, R. H., Rezaiemanesh, A., Karaji, A. G., & Salari, F. (2023) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2023.106781 · Cited by 13
Hoogeveen, R. C., Diffenderfer, M. R., Lim, E., Liu, C., Ikezaki, H., Guan, W., Tsai, M. Y., & Ballantyne, C. M. (2025) · Nutrients · doi:10.3390/nu17081324 · Cited by 13
“Clinical trials using apo(a) anti-sense and interleukin-6 blockade therapies are needed to show their potential efficacy in lowering Lp(a) levels and reducing ASCVD risk in individuals with elevated Lp(a) and chronic inflammation.”
Lejman-Larysz, K., Pietrzyk, D., Ćwiertnia, A., Kozłowski, M., Kwiatkowski, S., Szydłowska, I., Nawrocka-Rutkowska, J., Brodowski, J., Sowińska-Przepiera, E., Cymbaluk‐Płoska, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071953 · Cited by 12
“Serum hsCRP levels, along with the risk of cardiovascular problems, are decreased by statins, metformin, and lifestyle changes followed by weight loss [25,26].”
BackgroundArabi, S. M., Chambari, M., Bahrami, L. S., Hadi, S., & Sahebkar, A. (2024) · Current Hypertension Reviews · doi:10.2174/0115734021280797240212091416 · Cited by 11
Self-citationMahjoubin‐Tehran, M., Rezaei, S., Santos, R. D., Jamialahmadi, T., Almahmeed, W. A., & Sahebkar, A. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02151-8 · Cited by 11
Self-citationAhmadi, M., Askari, V. R., Shahri, B., Noghab, S. M. M., Jarahi, L., & Rahimi, V. B. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03330-1 · Cited by 11
“Besides, it has been noticed that lower hs-CRP levels are related to a reduced risk of future cardiovascular events (Carrero et al. 2019; Kandelouei et al. 2022).”
Koh, D., Choi, S., Park, J., Lee, S., Kim, H., Kim, I., & Park, D. (2023) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntad182 · Cited by 11
Prasad, K. (2024) · International Journal of Angiology · doi:10.1055/s-0044-1788296 · Cited by 11
Zhang, Y., Li, B., He, C., Fu, Y., & Zheng, Y. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.026 · Cited by 10
Hafezi, S. G., Ahari, R. K., Saberi‐Karimian, M., Giski, Z. E., Mansoori, A., Ferns, G. A., Ebrahimi, M., Heidari‐Bakavoli, A., Moohebati, M., Yousefian, S., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05122-w · Cited by 10
“Some of them (such as statins) have been proven to have potentially anti-inflammatory properties and reduce both hs-CRP and CRP levels [63].”
Wang, C., Huan, N., Wang, P.-L., Geng, Q., Ma, W., Ma, L., Jiang, H.-Y., Meng, X., Zhang, D., Gou, X.-J., et al. (2022) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-022-3688-3 · Cited by 10
Jamialahmadi, T., Reiner, Ž., Riahi, M. M., Kesharwani, P., Eid, A. H., Tayarani‐Najaran, Z., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673245069231010065055 · Cited by 11
Self-citationEffect of Statins on Superoxide Dismutase Level: A Systematic Review
Daliri, M., Simental‐Mendía, L. E., Jamialahmadi, T., Kesharwani, P., Reiner, Ž., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230831145809 · Cited by 9
Self-citationBersch-Ferreira, Â. C., Stein, E., Waclawovsky, G., da Silva, L. R., Machado, R. H. V., Weschenfelder, C., Figueiró, M. F., Suzumura, É. A., Santos, R. H. N., Duarte, G. B. S., et al. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03455-2 · Cited by 9
Exploring neutrophils as therapeutic targets in cardiometabolic diseases
Albiero, M., & Baragetti, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.003 · Cited by 9
The role of natural products as PCSK9 modulators: A review
Khayatan, D., Zare, K., Khanahmadi, M., Momtaz, S., Butler, A. E., Jamialahmadi, T., Almahmeed, W. A., Abdolghaffari, A. H., & Sahebkar, A. (2024) · Phytotherapy Research · doi:10.1002/ptr.8260 · Cited by 9
“More-over, statins possess many pleiotropic actions beyond LDL-C lowering (Bahrami et al., 2018; Bland et al., 2022; Gorabi et al., 2021; Kandelouei et al., 2022; Mollazadeh et al., 2021; Sahebkar et al., 2014; Serban et al., 2015; Vahedian-Azimi et al., 2021; Vahedian-Azimi et al., 2022;…”
Self-citationAslani, S., Eslami, M. M., Fakourizad, G., Faiz, A. F., Mohammadi, K., Dehghan, O., Imani, D., Abbaspour, A., Jamialahmadi, T., Razi, B., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00686-6 · Cited by 8
Self-citationRashidbeygi, E., Samarin, M. M., Sheikhhossein, F., Khalilkhaneh, A. H., Gholizadeh, M., Lohrasbi, N., Abbasi, A., Bazyar, H., Askari, G., & Amini, M. R. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70124 · Cited by 8
“The best-known member of the pentraxin family is C-reactive protein (CRP) [6], which is produced by the liver and by adipocytes in response to stress [7].”
Amlashi, M. A., Payahoo, A., Jafari-Maskouni, S., Dehghani, E., Talandashti, M. K., Ghelichi, Y., Nikoumanesh, M., Rezvani, S., Shahinfar, H., & Shidfar, F. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01744-8 · Cited by 8
“Among strategies for controlling CRP, lifestyle modifications and pharmacological interventions, including statins, have been widely investigated (Belanger et al. 2023; Hammonds et al. 2016; Kandelouei et al. 2022).”
Merashli, M., Bucci, T., Pastori, D., Pignatelli, P., & Ames, P. R. J. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06326-5 · Cited by 7
Babă, D.-F., Suciu, H., Avram, C., Danilesco, A., Moldovan, D.-A., Rauta, R. C., Huma, L., & Sin, I. A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043471 · Cited by 7
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Self-citationMachine learning-based prediction model for the efficacy and safety of statins
Xiong, Y., Liu, X., Wang, Q., Zhao, L., Kong, X., Da, C., Meng, Z., Qu, L., Xia, Q., Liu, L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1334929 · Cited by 7
Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study
Kouroupis, D., Zografou, I., Balaska, A., Reklou, A., Varouktsi, A., Paschala, A., Pyrpasopoulou, A., Stavropoulos, K., Vogiatzis, K., Sarvani, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12091960 · Cited by 7
“Statins are also effective in downregulating systemic inflammation, as shown by their potential to reduce CRP levels in patients with established cardiovascular disease [43].”
BackgroundThe protective effects of statins in traumatic brain injury
Pordel, S., McCloskey, A. P., Almahmeed, W. A., & Sahebkar, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00582-9 · Cited by 8
Self-citationStatins and adhesion molecules: a review of a novel pleiotropic property of statins
Sadeghi, M., Dehnavi, S., Shahbaz, S. K., Koushki, K., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2025) · Immunologic Research · doi:10.1007/s12026-025-09653-2 · Cited by 6
Self-citationAnti-inflammatory strategies for patients with atherosclerotic coronary disease
Imbesi, A., Greco, A., & Capodanno, D. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2564137 · Cited by 6
“As a result, current management strategies rely primarily on the pleiotropic effects of statins, which not only lower LDL cholesterol but also exert anti-inflammatory properties, as reflected by reductions in hs-CRP levels [63].”
Khrieba, M. O., Abdulelah, F. M., Alsaleh, N. A., AlRasheed, H. A., Ahmed, T. I., Mansy, A. E., Hamouda, M. A., Habba, E., Elshorbagi, N., Elhameed, A. G. A., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1690513 · Cited by 6
The Impact of Exercise on C-reactive Protein Levels in Hypertensive Patients: A Systematic Review
Kanthajan, T., Pandey, M., AlQassab, O., Sreenivasan, C., Parikh, A., Francis, A. J., & Nwosu, M. (2024) · Cureus · doi:10.7759/cureus.68821 · Cited by 6
“Additionally, CRP is produced by atherosclerotic lesions [6,7].”
BackgroundTHE RELATIONSHIP BETWEEN STATIN THERAPY AND AGE- RELATED MACULAR DEGENERATION – A SYSTEMATIC REVIEW
Dascălu, A. M. (2024) · FARMACIA · doi:10.31925/farmacia.2024.2.6 · Cited by 6
Guay, S., Paquette, M., Blais, C., Fortin, A., Bernard, S., & Baass, A. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae103 · Cited by 6
High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular
Bonardeaux, O. D. L. B., Deneye, M., Oury, C., Moonen, M. L., & Lancellotti, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041193 · Cited by 5
“A meta-analysis confirmed the efficacy of statins in reducing both CRP and hs-CRP levels [35].”
Effect of statins on psoriasis severity: A meta‐analysis of randomized clinical trials
Lopez, A., Martinez, E. C., Cruz, C. S., Xiao, T. S., Carcamo, Z. D. S., Reyes, A. M. A., Bonilla, F., Pineda, M. I. M., Herrera, E. J. S., Aguilar, A. J. A., et al. (2025) · Rheumatology & autoimmunity · doi:10.1002/rai2.12169 · Cited by 5
Chen, X., Wang, H., Sun, W., Lin, Z., Qiao, Z., Bian, X., Dong, Y., Feng, L., Zhu, C., Song, W., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s518383 · Cited by 5
Retiring the Term “Weighted Mean Difference” in Contemporary Evidence Synthesis
Lin, L., Xing, X., Han, W., & Tong, J. (2025) · Cochrane Evidence Synthesis and Methods · doi:10.1002/cesm.70051 · Cited by 5
“” [12] Another applied paper captions a forest plot as “ WMD and 95% CI, ” both implying study ‐ level WMDs [13].”
Genomic Insights Into Statin Therapy: Differential Expression Analysis of Key Genes
Mahjoubin‐Tehran, M., Sukhorukov, V. N., Jmaialahmadi, T., & Sahebkar, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102103 · Cited by 5
Self-citationIdentification and analysis of the molecular targets of statins in colorectal cancer
Firouzjaei, A. A., Mahmoudi, A. A., Almahmeed, W. A., Teng, Y., Kesharwani, P., & Sahebkar, A. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155258 · Cited by 5
Self-citationRole of high‑sensitivity C‑reactive protein in patients with sarcoma
Pedersen, N. A., Baad‐Hansen, T., Møller, H. J., & Sandfeld‐Paulsen, B. (2023) · Oncology Letters · doi:10.3892/ol.2023.14118 · Cited by 5
“This allows for detecting and graduating low‑grade inflam‑ matory states such as obesity, diabetes, and cardiovascular disease (20,21).”
BackgroundGao, D., Hua, R., Jiesisibieke, D., Ma, Y., Li, C., Wu, S., Ma, Q., & Xie, W. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.989527 · Cited by 5
“It is thought that the roles of CRP in the development of atherosclerotic plaque are complicated (52).”
BackgroundStatins - From Lipid-Lowering Benefits to Pleiotropic Effects
Liu, D. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001540 · Cited by 5
Kim, E. N., Seok, H., Koh, J., Yang, W., Lee, G. H., Choi, W. H., Lim, J. S., Ok, Y. J., Choi, J. S., Kim, C. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.22.581315 · Cited by 5
Shen, X., Chen, L., Shen, L., Chen, S., Mu, S., Chen, L., Wang, S., & Li, Z. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1634369 · Cited by 4
“This provides evidence for statin therapy to improve prognosis through regulating lipid metabolism and exerting anti-inflammatory effects (45).”
Li, Y., Sun, M., Li, R., Dou, M., Dong, H., Xue, L., & Sun, G. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-45 · Cited by 4
Inflammation—The new treatment target for ischaemic stroke prevention
Gorey, S., McCabe, J. J., & Kelly, P. J. (2023) · Frontiers in Stroke · doi:10.3389/fstro.2023.1241506 · Cited by 4
Sarabi, P. Z., Moradi, M., Bagheri, M., Khalili, M. R., Moradifard, S., Jamialahmadi, T., Ghasemi, F., & Sahebkar, A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206271583231206052403 · Cited by 5
Self-citationKarami, J., Razi, B., Imani, D., Aslani, S., Pakjoo, M., Fasihi, M., Mohammadi, K., & Sahebkar, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128285148240122112045 · Cited by 4
Self-citationAssociation of hs-CRP with Serum Creatinine Levels in Chronic Kidney Diseases
Goriya, S., & Priya, N. (2024) · Indian journal of clinical medicine · doi:10.1177/26339447241287048 · Cited by 4
Zhang, N., Ren, Y., Qin, D., Yang, X., Chen, Z., & Zhao, L. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s515436 · Cited by 4
“27 Vascular endothelial function is also regulated by nitric oxide (NO) and endothelin-1 (ET-1), two key molecules secreted by endothelial cells.”
van Bruggen, F. H., & Diamond, D. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103569 · Cited by 4
“In addition, statins reduce C-reactive protein (CRP) and hs-CRP levels in patients with CVD, independent of LDL-C levels [84].”
Özkan, C., & Karayiğit, O. (2023) · Angiology · doi:10.1177/00033197231176983 · Cited by 4
Giral, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac329 · Cited by 4
Kim, E. N., Seok, H., Koh, J., Bae, J. M., Yang, W., Lee, G. H., Choi, W. H., Lim, J. S., Ok, Y. J., Choi, J. S., et al. (2025) · Translational research · doi:10.1016/j.trsl.2025.05.008 · Cited by 3
Bergo, I., SLEVIN, M. A., Pastorello, Y., Höhne, A., & Tero-Vescan, A. (2025) · Life · doi:10.3390/life15101593 · Cited by 3
“Thus, beyond lipid control, their pleiotropy provides a mechanistic rationale for modulating the FgDP–IL-6 axis in thromboinflammatory states [90,91].”
Fathian, F., Divkovic, I., Strømme, M. F., Mykletun, A., Kroken, R. A., Bartz-Johannessen, C. A., & Johnsen, E. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101133 · Cited by 3
Kakehi, K., Ueno, M., Kayama, M., Yamada, N., Onishi, K., Sugimoto, K., Funauchi, Y., Kawamura, T., Fujita, K., Matsuzoe, H., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05395-z · Cited by 3
“When lipid components are reduced through therapy, inflammation is alleviated, vasodilatory capacity is restored, and blood flow resistance decreases, potentially improving coronary flow as measured by QFR [27].”
Mashaba, R. G., Phoswa, W. N., & Mokgalaboni, K. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11090276 · Cited by 3
Khodarahmi, M., Seyedhosseini-Ghaheh, H., & Askari, G. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70566 · Cited by 3
“In contrast, pharmacological approaches such as statin therapy often produce larger reductions, typically by up to 60% (0.6–3 mg/L) (Asher and Houston 2007; Xie et al. 2024; Kandelouei et al. 2022), particularly in individuals at high cardiovascular risk (Kandelouei et al. 2022).”
InfluentialJamialahmadi, T., Reiner, Ž., Riahi, M. M., Emami, S. A., Tayarani‐Najaran, Z., Salehabadi, S., Kesharwani, P., Al‐Rasadi, K., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230918114451 · Cited by 3
Self-citationRazi, B., Imani, D., Aslani, S., Reiner, Ž., & Sahebkar, A. (2024) · Current Drug Targets · doi:10.2174/0113894501302428240909150925 · Cited by 3
Self-citationĐukić, L., Trajković, L., Knežević, T., Dimitrijević, J., Krstic, D. Z., & Stojanović, M. (2022) · Dose-Response · doi:10.1177/15593258221126827 · Cited by 3
“The C-reactive protein (CRP) is a member of the pentraxin protein family that is produced by liver cells.(1) In smaller amounts, CRP can be produced by some other cells such as vascular smooth muscle cells and macrophages, which can partly explain the possibility to use this biomarker in different fields of biomedicin…”
BackgroundGao, Y., Zhao, K., Liu, J., Zhang, X., Gong, L., Zhou, X., & Chen, G. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.70003 · Cited by 2
Ghotbi, E., Hathaway, Q. A., Hadidchi, R., Bancks, M. P., Bluemke, D. A., Wan, M., Barr, R. G., Post, W. S., Budoff, M. J., Smith, B. M., et al. (2025) · Bone · doi:10.1016/j.bone.2025.117659 · Cited by 2
Beyond Anatomy: The Combined Power of SYNTAX Score and Inflammatory Biomarkers in CABG Outcomes
Toprak, B. (2025) · JOURNAL OF CARDIO-VASCULAR-THORACIC ANAESTHESIA AND INTENSIVE CARE SOCIETY · doi:10.14744/gkdad.2025.46794 · Cited by 2
“[7,14] CRP reflects heightened preoperative inflammation and has been associated with infarct size, tissue injury, and the surgical stress response.”
Tooth loss is associated with subsequent brain white matter degradation up to over a decade
Tian, Q., Qi, X., Greig, E. E., Landman, B. A., Davatzikos, C. A., Resnick, S. M., Wu, B., & Ferrucci, L. (2026) · Journal of Dentistry · doi:10.1016/j.jdent.2026.106732 · Cited by 2
Noormandi, A., Bugger, H., Aziz, F., Miličević, Z., von Lewinski, D., LUDVIK, B., Parzer, V., Zirlik, A., Pieber, T. R., Dimai, H. P., et al. (2026) · Obesity Facts · doi:10.1159/000553324 · Cited by 2
“Statin therapy results in decreased levels of hs-CRP and helps maintain stable plaques regardless of LDL-cholesterol level [171, 172].”
Metadata
- Authors
- Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., & Sahebkar, A.
- Affiliations
- University of Utah (US)
- Rafsanjan University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
- Tarbiat Modares University (IR)
- Mashhad University of Medical Sciences (IR)
- University Hospital Centre Zagreb (HR)
- Corresponding author
- Razi, Bahman
- Sahebkar, Amirhossein
- ORCID
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2022-01-28
- Volume
- 2022
- Pages
- 1-20
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC8816584
- OpenAlex
- W4210294380
- Cited by
- 136
- References
- 101
- Citations by year
- 2026: 18 · 2025: 35 · 2024: 38 · 2023: 30 · 2022: 14
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, high-sensitivity C-reactive protein, C-reactive protein, cardiovascular disease, anti-inflammatory activity, statin intensity, treatment duration
- MeSH terms
- C-Reactive Protein, Cardiovascular Diseases, Humans, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.